Chinese biochemical company signs MoU with Melbourne University

10 Oct 2018

The University of Melbourne has signed a memorandum of understanding (MoU) with Beijing First Biochemical Pharmaceutical (First Bio-Pharma) to fund research in Australia.

The MoU will fund the university to deliver biotechnology research, and longer term, enable students to travel abroad to conduct further biotech studies. It will also help the university’s researchers leverage commercialisation and market access opportunities in China.

‘The MoU is important in that it provides a real boost to our researchers, in part through funding, and more importantly through access to First Bio-Pharma’s significant connections and capabilities as a global biotech business,’ says Professor James McCluskey, University of Melbourne’s Deputy Vice-Chancellor of Research in a media release.

‘The company owns first class research labs, a Good Manufacturing Practice–certified production line and a sales net of 8,000 hospitals,’ says Bowen Zhang, Chairman of First Bio-Pharma.

‘We have built up cooperative relationships with Chinese Academy of Science, Chinese Academy of Medical Sciences and Peking University. The University of Melbourne is the leading university in Australia and the world, and we see the MoU as delivering widespread benefits for both our company and the university, through collaborative research and internships.

‘This is an exciting time for the bio-pharmaceutical industry and we are pleased that we can work with the university to deliver outcomes that will benefit us both, and the wider community through leading-edge research projects.’

A global leader in medical research, Australia offers investment opportunities ranging from discovery research through to product development partnerships in biotech, pharmaceuticals, medical devices, tropical medicines and digital health. Find out more.